PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services inthe United States, announced that it was selected by Insmed as part of the network of specialty pharmacies to dispenseBRINSUPRI™ (brensocatib), a once daily oral medication to treat non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.1 2
https://mma.prnewswire.com/media/955325/PANTHERx_Rare_Logo.jpg
“The PANTHERx team is pleased to be chosen by Insmed to dispense BRINSUPRI™, the first and only FDA-approved treatment for NCFB,” said Bansi Nagji, CEO, PANTHERx® Rare Pharmacy.
About PANTHERx Rare PANTHERx Rareis a specialty pharmacy exclusively focused on rare and orphan diseases, distributing several orphan products, and providing access and support services to those needing them most. Known as The Rare Disease Pharmacy®, PANTHERx transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to people living with rare and devastating conditions.
PANTHERx is a dual-accredited specialty pharmacy, holding distinctions in rare disease including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and Utilization Review Accreditation Commission (URAC) Rare Disease Center of Excellence.As a pharmacy focused on patient satisfaction, PANTHERx is the eight-time winner of the prestigious MMIT Patient Choice Award, including the 2025 honor. PANTHERx is headquartered inPittsburgh,Pennsylvaniaand is licensed in all 50 states and U.S. territories.
CONTACT: For more information, please emailTheRareSP@pantherxrare.comor visit www.pantherxrare.com.
https://c212.net/c/img/favicon.png?sn=NE50634&sd=2025-08-13
View original content to download multimedia:https://www.prnewswire.com/news-releases/pantherx-rare-selected-by-insmed-to-dispense-brinsupri-brensocatib-for-the-treatment-of-non-cystic-fibrosis-bronchiectasis-302528964.html
SOURCE PANTHERx Rare Pharmacy
https://rt.newswire.ca/rt.gif?NewsItemId=NE50634&Transmission_Id=202508130830PR_NEWS_USPR_____NE50634&DateId=20250813